Kala Pharmaceuticals Names Gregory Perry to Board of Directors, Chair of Audit Committee
6 March 2018 - - Waltham, Massachusetts-based biopharmaceutical company Kala Pharmaceuticals, Inc. (NASDAQ: KALA) has appointed Gregory Perry to the company's board of directors and as chair of its audit committee, the company said.
Perry has served as audit committee chair at Merus N.V. since 2016. He served as chief financial and administrative officer at Aegerion Pharmaceuticals Inc. from 2015 until the company's merger with Novelion Therapeutics Inc., after which he served as chief financial and administrative officer at Novelion until 2017.
Prior to joining Aegerion, Perry held the role of chief financial and business officer at Eleven Biotherapeutics, Inc. from 2014-2015. He was a member of the board of directors, audit committee chair and compensation committee member at Ocata Therapeutics, Inc. from 2011 until the company was acquired by Astellas Pharma Inc. in 2016.
Perry holds a Bachelor of Arts Degree in Economics and Political Science from Amherst College.
Kala is focused on the development and commercialisation of therapeutics using its proprietary mucus-penetrating particle (MMP) technology, with an initial focus on the treatment of eye diseases.